Gregory Scott Stein
Tulane University is actively seeking commercial entities to further develop and commercialize a novel biomarker-based diagnostic to help determine the aggressiveness of a patient's cancer and the types of treatment that may be most effective.
This technology has been tested extensively in vitro. Laboratory work is ongoing for further data and to understand other predictive capabilities of the biomarker.
Tulane University, New Orleans, LA 70118 504-865-5000 email@example.com